Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT03236415 Withdrawn - Clinical trials for Coronary Artery Disease

Comparative Response to Vascular Injury in Patients With Diabetes Mellitus: An OCT Study of BVS Versus Xience DES

Start date: August 2017
Phase: N/A
Study type: Interventional

Stents are used at centers around the world to unblock the arteries of the heart. These stents are usually made of metal and remain permanently within the blood vessel wall. Newer developments in the stent technology has led to stent scaffolds that can be reabsorbed over time. Patients with diabetes are prone to more complex blockages in the heart arteries which can be more difficult to treat. The purpose of this study is to compare the difference of how arteries heal early when metal stents or resorbable stents are used in patients with diabetes.

NCT ID: NCT02735993 Withdrawn - Clinical trials for Coronary Artery Disease

Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells

Start date: October 2014
Phase: N/A
Study type: Observational [Patient Registry]

This cardiac registry study will collect information from patients with ischemic or non-ischemic heart failure that have been treated with adipose-derived regenerative cells (ADRCs) delivered via intramyocardial injection.

NCT ID: NCT02723981 Withdrawn - Coronary Disease Clinical Trials

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials

Start date: April 2016
Phase: Phase 4
Study type: Interventional

Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate - the incidence of bleedings (COSTA-Bleed) and - the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with the abluminal sirolimus coated bio-engineered stent (COMBO stent) in association with short-term single antiplatelet therapy as compared to a guidelines-based strategy in patients with coronary artery disease with an indication for chronic oral anticoagulant therapy.

NCT ID: NCT02611596 Withdrawn - Type 2 Diabetes Clinical Trials

Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics

Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this investigation is to compare subjects at high risk for silent myocardial ischemia in the placebo group to subjects at high risk for silent myocardial ischemia in the ranolazine group to determine if ranolazine can be used as a treatment to decrease silent myocardial ischemia (SMI). Subjects at high risk for silent myocardial ischemia are defined in this protocol as diabetics with stable ischemic heart disease. This study will look at the impact ranolazine treatment has on biomarkers that have been shown to be highly associated with increased risk of morbidity and mortality in relation to SMI. If the hypothesis is correct, further studies can be conducted to determine if treatment with ranolazine has impact on long-term outcomes such as hospitalizations, myocardial infarction, congestive heart failure or sudden cardiac death.

NCT ID: NCT02597283 Withdrawn - Clinical trials for Coronary Artery Disease

Coronary Bifurcation Lesions Treated With Biguard Stent System

Start date: December 2015
Phase: N/A
Study type: Interventional

This study is designed to test the hypothesis that the Biguard stent system will lead to fewer target lesion failure compared to regular stent system in patients with coronary bifurcation lesions at one year.

NCT ID: NCT02454426 Withdrawn - Clinical trials for Coronary Artery Disease

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Start date: April 2016
Phase: Phase 0
Study type: Interventional

This is a preliminary, open-label, clinical trial designed to assess the efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients with coronary artery disease. In addition, the study will assess the effects of vortioxetine on heart rate variability in these patients.

NCT ID: NCT02423265 Withdrawn - Clinical trials for Coronary Artery Disease

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

Start date: June 2015
Phase: Phase 4
Study type: Interventional

Anti-anginal drugs relieve ischemia and symptoms by reducing myocardial oxygen demand by reducing heart rate and or contractility (beta-blockers, phenylalkylamine and benzothiazepineate classes of calcium antagonists) or vasodilatation of the venous system (fall in pre-load) and coronary vessels. Late sodium channels remain open for longer in the presence of myocardial ischaemia. Ranolazine, a novel anti-anginal agent, acts by inhibiting the inward late inward sodium current (INaL), reducing intracellular sodium accumulation and consequently intracellular calcium overload via the sodium/calcium exchanger. It is currently thought that this reduction in intracellular calcium reduces diastolic myocardial stiffness and therefore compression of the small coronary vessels. There is considerable animal data to support this theory. There are good theoretical reasons to postulate that patients with chronically occluded vessels may derive less benefit from conventional anti-anginal agents, particularly vasodilators. The ischemic myocardium, subtended by the occluded vessel, will already be subject to significant concentrations of paracrine vasodilators such as adenosine. Ranolazine, therefore, may on the basis of its mechanism of action, provide greater relief of ischemia in such patients than conventional anti-anginal agents.

NCT ID: NCT02418143 Withdrawn - Coronary Disease Clinical Trials

A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope

Start date: September 2015
Phase: N/A
Study type: Observational

Actively gather additional information on the use of CorMatrix CanGaroo ECM Envelope in a post market observational study.

NCT ID: NCT02379403 Withdrawn - Clinical trials for Cardiovascular Disease

Effects of Tart Cherry and Aroniaberry Supplementation on Endothelial Function and Cardiovascular Measures in Healthy Older Adults: Interactions With Genotype and Proteome

Start date: February 19, 2015
Phase: N/A
Study type: Observational

Background: - Heart disease is the leading cause of death and disabilities in the United States. Diets high in fruits and vegetables may reduce the risk of heart disease. Fruits, including red tart cherries and purple aroniaberries, may be especially beneficial. Researchers want to know how tart cherry and aroniaberry extracts affect heart health. Objective: - To study the benefits of tart cherry and aroniaberry extract on vascular function and other measures. These include inflammation, oxidation, and cholesterol. Eligibility: - Men and post-menopausal women ages 55 70 in good health and with normal or slightly high blood pressure or cholesterol. Design: - Participants will be screened with a physical exam, medical history, and blood tests. - Participants will have 6 visits. They will have blood taken at every visit. - Visit 1: - Blood vessel tests. Participants will lie down. Heart rhythm will be monitored. A device will be placed on the upper arm, and pictures of blood vessels will be taken. - A blood pressure cuff will be tightened around the lower arm for 5 minutes. - Cardio-Ankle-Vascular Index (CAVI). Blood pressure cuffs will be placed on both arms and legs. They will be tightened with air at the same time for a few minutes. - Participants will be assigned to one of three groups. For 3 weeks each, in random order, they will take: aroniaberry capsules, tart cherry capsules, placebo capsules, and no capsules. - Participants will answer questions online about their eating and exercise. - Participants will be keep a record of what they eat for a few periods. They will come for a study visit every 3 weeks through week 15.

NCT ID: NCT02377336 Withdrawn - Clinical trials for Ischemic Heart Disease

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Start date: May 2015
Phase: Phase 2
Study type: Interventional

This study will evaluate the effect of GS-6615 in adults with chronic stable angina and coronary artery disease (CAD) receiving a stable daily dose of up to 2 antianginal medications. The study will consist of two periods: a 1 to 3 week Qualifying Period and a Treatment Period lasting 13 days (± 3 days). During the Qualifying Period and at the end of the Treatment Period, participants will undergo exercise tolerance testing.